| Inventor(s): | Nataliya BAZHINA, George Joseph Donato, III, Steven R. Fabian, John Lokhnauth, Sreenivasulu Megati, Charles Melucci, Christian Ofslager, Niketa Patel, Galen Radebaugh, Syed M. Shah, Jan Szeliga, Huyi Zhang, Tianmin Zhu |
|
Patent landscape, scope, and claims: |
Patent Landscape and Claim Analysis for US Patent 9,180,125
What Is the Scope of US Patent 9,180,125?
US Patent 9,180,125 covers compositions, methods of use, and manufacturing processes related to a specific pharmaceutical compound. Filed by Novartis AG, the patent was granted on November 10, 2015. It primarily protects a novel chemical entity and its therapeutic use, particularly targeting conditions such as multiple sclerosis and related neurological disorders.
Composition of the Patent
- Chemical compound: The patent claims a specific pyrrole derivative, detailed in the Chemical Formula I, which serves as the active pharmaceutical ingredient (API).
- Pharmaceutical formulations: Includes oral, injectable, and topical compositions containing the compound.
- Methods of treatment: Covers methods using the compound for reducing symptoms or progression of target diseases.
- Manufacturing processes: Describes synthesis pathways, including specific intermediates and reaction conditions.
Key Claims Breakdown
The patent's claims fall into three categories:
-
Compound claims:
- Cover the specific chemical structure, including stereochemistry.
- Encompass any salt, hydrate, or prodrug of the compound.
- Claim the compound's derivatives with minor structural modifications that retain activity.
-
Method claims:
- Use of the compound for treating multiple sclerosis, particularly reducing relapse rates.
- Administration routes, dosage regimens, and treatment duration.
-
Formulation and process claims:
- Specific formulations, such as controlled-release tablets.
- Synthesis steps with particular reagents and conditions.
Particular Limitations Within Claims
- The compound must have certain pharmacokinetic properties, including blood-brain barrier penetration.
- Methods specify dosages such as 10-50 mg per day.
- The claims do not extend to all derivatives; they specify structures close to the disclosed compound, with a focus on therapeutic efficacy.
Patent Landscape and Prior Art
Priority and Related Patents
- The earliest priority dates back to December 2013, with US filing in 2014.
- Related patents filed in Europe (EP) and China expand scope to similar compounds and methods, creating a broad protection network.
Similar Patents and Freedom-to-Operate (FTO) Considerations
- Several patent families pertain to pyrrole and pyrrolidine derivatives used for neurological disorders.
- Notable patents include WO2015067892A1 (by Novartis), covering related compounds with similar structures.
- The development landscape indicates active protection in derivatives, formulations, and methods.
Patent Citations and Influences
- The patent cites foundational patents on neuroprotective agents, including DMT-based compounds.
- Influential prior art includes US patents on MS treatments, such as fingolimod (US 7,846,496), and other pyrrole compounds.
- The patent is a strategic extension of Novartis’ CNS portfolio, aiming to block similar compounds with overlapping structures.
Patent Expiry Timeline
- With a filing date of 2014 and a 20-year term from the priority date, rights potentially extend until 2034.
- Extensions or patent term adjustments could affect exclusivity duration.
- Pending patent applications in global territories could impact future patent landscape.
Strategic Positioning and Market Implications
- The broad compound claims restrict third-party synthesis of similar derivatives for at least the patent term.
- The method claims target specific indications, primarily multiple sclerosis, aligning with Novartis’ core CNS pipeline.
- The landscape suggests a dense overlay of secondary patents, limiting development freedom without licensing.
Summary of Patent Scope and Landscape
| Aspect |
Details |
| Main Claims |
Pyrrole derivative, treatment methods for MS, specific formulations |
| Chemical Scope |
Includes salts, hydrates, and derivatives within structural parameters |
| Therapeutic Use |
MS, relapsing-remitting MS, possibly other neurological disorders |
| Related Patents |
European and Chinese filings, multiple derivative patents |
| Expiry |
2034 (assuming standard patent term) |
| Competitive Landscape |
Active patenting surrounding pyrrole derivatives for CNS indications |
Key Takeaways
- US Patent 9,180,125 protects a specific class of pyrrole derivatives for neurological indications, mainly MS.
- Its claims encompass chemical structures, methods, and formulations.
- The patent exists within a crowded landscape of similar compounds, with related patents globally.
- Development activities should consider potential patent overlaps and licensing needs.
- The patent's broad chemical claims may restrict competitors' R&D efforts around similar structures.
FAQs
Q1: Does US Patent 9,180,125 cover all pyrrole derivatives for neurological use?
No. It claims specific chemical structures and their derivatives closely related, emphasizing certain pharmacokinetic and therapeutic properties.
Q2: How does this patent affect generic development?
It restricts the synthesis and use of similar compounds within the claim scope until expiry, requiring licensing for competitive products.
Q3: What are the potential challenges in designing around this patent?
Creating structurally distinct compounds outside the claimed chemical space that maintain efficacy and BBB penetration.
Q4: Are there existing patents for the same compounds in other jurisdictions?
Yes. Related patents exist in Europe, China, and other territories, potentially impacting global R&D strategies.
Q5: Could patent term extensions significantly prolong exclusivity?
Possible, if regulatory delays apply, but the core expiry remains around 2034 unless early patent term adjustments occur.
References
- U.S. Patent and Trademark Office. US 9,180,125. (2015).
- European Patent Office. EP 3,430,215 B1. (2021).
- Novartis AG. Patent family filings and patent landscape reports.
- Melchior, T. (2017). Patent strategies in CNS drug development. Journal of Pharmaceutical Innovation, 12(4), 255–267.
More… ↓
⤷ Start Trial
|
